Press Releases Keyword Search Year None2023202220212020201920182017 June 7, 2023 FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy June 6, 2023 FibroGen to Present at Upcoming Investor Conferences May 18, 2023 FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia May 8, 2023 FibroGen Reports First Quarter 2023 Financial Results May 8, 2023 FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics May 5, 2023 FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS) May 1, 2023 FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value April 24, 2023 FibroGen to Report First Quarter 2023 Financial Results April 3, 2023 FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis February 27, 2023 FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results February 27, 2023 FibroGen to Present at Cowen’s 43rd Annual Health Care Conference February 17, 2023 FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results February 2, 2023 FibroGen to Present at SVB Securities Global Biopharma Conference
